ACE Share Price Performance
SEK 3.00
-0.78 (-20.63%)
52.5% undervalued intrinsic discount
SEK 6.32
Fair Value
Price SEK 3.00
AnalystConsensusTarget SEK 6.32
AnalystLowTarget SEK 3.95
AnalystHighTarget SEK 8.50
Fair ValueSEK 6.32
Share Pricen/a
Ascelia Pharma AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
ACE Community Narratives
AN
Fair Value
·Fair Value SEK 6.32 52.5% undervalued intrinsic discount
Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value SEK 3.95 24.1% undervalued intrinsic discount
Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 8.5 64.7% undervalued intrinsic discount
Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes drugs in rare oncology, with a focus on liver imaging and oral chemotherapy. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 6.32
52.5% undervalued intrinsic discount
Fair Value
Profit Margin
53.52%
Future PE
30.17x
Price in 2029
SEK 0
Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 3.95
24.1% undervalued intrinsic discount
Fair Value
Profit Margin
56.62%
Future PE
16.78x
Price in 2029
SEK 0
Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare, cancer related conditions. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 8.5
64.7% undervalued intrinsic discount
Fair Value
Profit Margin
55.9%
Future PE
37.07x
Price in 2029
SEK 0
Trending Discussion
Recently Updated Narratives
AN
Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative
Fair Value: SEK 6.32 52.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus
Fair Value: SEK 3.95 24.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential
Fair Value: SEK 8.5 64.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ascelia Pharma AB (publ) Key Details
About ACE
- Founded
- 1999
- Employees
- 10
- CEO
- WebsiteView website
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
Recent ACE News & Updates
Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?
